Tuesday, April 13, 2020
Altimate Health Corporation and Massachusetts General Hospital announced that they have signed a collaboration agreement for joint research, development, and commercialization in the emerging field of precision psychiatry. This is expected to lead to groundbreaking advances in the treatment of conditions including depression, substance use disorders, and serious mental illness including schizophrenia and bipolar disorder.
Dr. Maurizio Fava, Chief of Psychiatry at Massachusetts General Hospital (MGH), and a member of the scientific advisory board of Altimate, commented that “We have an opportunity to lead the development of ‘precision psychiatry’, which can account for individual differences in biology, environment and lifestyle, so we can develop more targeted and effective approaches to prevention, diagnosis, and treatment.”
“This collaboration allows us to accelerate the pace and impact of data-driven precision medicine to improve the health and well-being of people with behavioral health and psychiatric disorders”, according to Paul Pyzowski, CEO of Altimate.
According to Dr. Wasim Malik, Managing Director of Iaso Ventures, and an Altimate board member and co-founder, “The recent pandemic has brought much needed attention to the prevalence of mental illness. Digital health solutions are critical for physicians, insurers, and pharmaceutical companies to be able to address this ongoing public health crisis.”
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of “America’s Best Hospitals.”
Altimate Health is a Boston-based company founded to improve outcomes in people with behavioral health and psychiatric conditions through the innovative use of healthcare data, machine learning and artificial intelligence. The founding team includes executives with established track records in pharma, medtech, healthcare, and computer science.
MGH Contact
Noah Brown, Senior Public Affairs & Media Relations Officer
Massachusetts General Hospital • 125 Nashua St • Suite 220 • Boston, MA 02114
617-643-3907 • nbrown9@partners.org